Intra-Cellular Therapies (ITCI) Short Interest Ratio & Short Volume → Elon’s New A.I. Device is About to Shock the World (From InvestorPlace) (Ad) Free ITCI Stock Alerts $73.60 +0.34 (+0.46%) (As of 01:07 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Intra-Cellular Therapies Short Interest DataCurrent Short Volume3,590,000 sharesPrevious Short Volume3,470,000 sharesChange Vs. Previous Month+3.46%Dollar Volume Sold Short$232.49 millionShort Interest Ratio / Days to Cover3.7Last Record DateApril 15, 2024Outstanding Shares96,810,000 sharesPercentage of Shares Shorted3.71%Today's Trading Volume179,076 sharesAverage Trading Volume929,482 sharesToday's Volume Vs. Average19% Short Selling Intra-Cellular Therapies ? Sign up to receive the latest short interest report for Intra-Cellular Therapies and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatITCI Short Interest Over TimeITCI Days to Cover Over TimeITCI Percentage of Float Shorted Over Time Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. Intra-Cellular Therapies Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20243,590,000 shares $232.49 million +3.5%N/A3.7 $64.76 3/31/20243,470,000 shares $240.12 million +4.8%N/A4.5 $69.20 3/15/20243,310,000 shares $214.42 million -10.5%N/A4.1 $64.78 2/29/20243,700,000 shares $257.22 million -4.2%N/A4.3 $69.52 2/15/20243,860,000 shares $289.08 million -5.2%N/A4.4 $74.89 1/31/20244,070,000 shares $274.07 million +16.0%N/A4.9 $67.34 Get the Latest News and Ratings for ITCI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. 1/15/20243,510,000 shares $232.92 million -7.9%N/A3.8 $66.36 12/31/20233,810,000 shares $272.87 million +5.8%N/A4 $71.62 12/15/20233,600,000 shares $235.58 million -8.4%N/A3.9 $65.44 11/30/20233,930,000 shares $241.18 million +15.3%N/A4.5 $61.37 11/15/20233,410,000 shares $193.31 million +7.9%N/A4.1 $56.69 10/31/20233,160,000 shares $157.24 million +17.9%N/A3.9 $49.76 10/15/20232,680,000 shares $143.81 million -4.6%N/A3.9 $53.66 9/30/20232,810,000 shares $146.37 million +26.0%N/A4.3 $52.09 9/15/20232,230,000 shares $122.72 million -12.6%N/A3.5 $55.03 8/31/20232,550,000 shares $141.58 million +0.4%N/A4 $55.52 8/15/20232,540,000 shares $146.86 million +25.1%N/A4 $57.82 7/31/20232,030,000 shares $125.54 million -16.8%N/A3.1 $61.84 7/15/20232,440,000 shares $154.99 million -6.2%N/A3.4 $63.52 6/30/20232,600,000 shares $164.63 million -22.2%N/A3.5 $63.32 6/15/20233,340,000 shares $214.66 million -2.9%N/A4 $64.27 5/31/20233,440,000 shares $204.27 million -3.4%N/A4.2 $59.38 5/15/20233,560,000 shares $231.08 million +21.9%N/A4 $64.91 4/30/20232,920,000 shares $181.48 million -9.6%N/A3.3 $62.15 4/15/20233,230,000 shares $194.48 million -3.0%N/A3.9 $60.21 3/31/20233,330,000 shares $180.32 million +27.6%N/A4.1 $54.15 3/15/20232,610,000 shares $114.32 million -21.2%N/A3.9 $43.80 2/28/20233,310,000 shares $162.29 million +37.9%N/A5 $49.03 2/15/20232,400,000 shares $120 million -8.8%N/A4 $50.00 1/31/20232,630,000 shares $126.03 million +1.5%N/A4.6 $47.92 1/15/20232,590,000 shares $124.40 million -19.3%N/A4.1 $48.03 12/30/20223,210,000 shares $169.87 million +7.4%N/A5.1 $52.92 12/15/20222,990,000 shares $154.97 million +7.2%N/A4.6 $51.83 11/30/20222,790,000 shares $151.27 million -12.3%N/A4.1 $54.22 11/15/20223,180,000 shares $161.10 million -21.7%N/A4.5 $50.66 10/31/20224,060,000 shares $185.42 million +1.0%N/A5.3 $45.67 10/15/20224,020,000 shares $188.82 million -1.5%N/A5.5 $46.97 9/30/20224,080,000 shares $189.84 million +7.4%N/A5.6 $46.53 9/15/20223,800,000 shares $192.01 million +15.5%N/A5.1 $50.53 8/31/20223,290,000 shares $165.36 million -12.0%N/A4.4 $50.26Elon’s New A.I. Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. ITCI Short Interest - Frequently Asked Questions What is Intra-Cellular Therapies' current short interest? Short interest is the volume of Intra-Cellular Therapies shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 3,590,000 shares of ITCI short. Learn More on Intra-Cellular Therapies' current short interest. What is a good short interest ratio for Intra-Cellular Therapies? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ITCI shares currently have a short interest ratio of 4.0. Learn More on Intra-Cellular Therapies's short interest ratio. Which institutional investors are shorting Intra-Cellular Therapies? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Intra-Cellular Therapies: Simplex Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Intra-Cellular Therapies' short interest increasing or decreasing? Intra-Cellular Therapies saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 3,590,000 shares, an increase of 3.5% from the previous total of 3,470,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Intra-Cellular Therapies' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Intra-Cellular Therapies: Viking Therapeutics, Inc. (10.12%), Jazz Pharmaceuticals plc (6.14%), Cytokinetics, Incorporated (13.91%), Cerevel Therapeutics Holdings, Inc. (9.10%), Elanco Animal Health Incorporated (3.14%), Ionis Pharmaceuticals, Inc. (7.12%), Ascendis Pharma A/S (6.18%), Apellis Pharmaceuticals, Inc. (8.85%), Legend Biotech Co. (6.04%), Blueprint Medicines Co. (6.94%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Intra-Cellular Therapies stock? Short selling ITCI is an investing strategy that aims to generate trading profit from Intra-Cellular Therapies as its price is falling. ITCI shares are trading up $0.34 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Intra-Cellular Therapies? A short squeeze for Intra-Cellular Therapies occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ITCI, which in turn drives the price of the stock up even further. How often is Intra-Cellular Therapies' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ITCI, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: VKTX Short Interest Data JAZZ Short Interest Data CYTK Short Interest Data CERE Short Interest Data ELAN Short Interest Data IONS Short Interest Data ASND Short Interest Data APLS Short Interest Data LEGN Short Interest Data BPMC Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ITCI) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm Press